wire report
STAT+: Novo underwhelmed by drug it once fought Pfizer for
Revolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech news
coverage / news / attributed
Get updates, read source context, send useful records, share the story, or support the reporting work from the reading page.
Revolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech news
Use the references, response options, and updates before treating any contested detail as complete.
Open topic path or search related wording such as records, sources, agencies, dates, and locations.
What happened
According to STAT’s source item, STAT+: Novo underwhelmed by drug it once fought Pfizer for, Revolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech news
Context
The development sits in VINI’s Science file for readers following research, health, climate, space, medicine, and scientific institutions. The original report is linked so readers can check the source account, follow later updates, and compare new coverage against the first published record. The source item is dated 2026-06-08T14:05:38+00:00.
What to watch
Open questions include whether primary sources issue follow-up statements, whether local or market impacts become clearer, and whether additional reporting changes the timeline or adds material context.
Source
Primary source: STAT+: Novo underwhelmed by drug it once fought Pfizer for via STAT. VINI cites and links the source; it does not reproduce the publisher’s full article text without rights clearance.
Keep following
This file can keep developing
vininews.com uses reader tips, public records, right-of-reply requests, corrections, and follow-up reporting to keep important stories current.
Support and subscriptions never buy coverage, placement, suppression, or corrections.
Reader comments
Moderated discussion
Comments are open to authenticated approved accounts, screened for spam and abuse, and published only after newsroom moderation unless editors change the story control.
No approved comments yet.
Substantive, civil comments can be submitted by approved account holders.